Is the clinical impact of nonalcoholic fatty liver disease (NAFLD) the Y2K of our specialty? Have we fashioned a mountain from a molehill of end-stage liver disease? The answer merits some consideration.
Ian Wanless’s landmark cross-sectional study reported convincingly that the overall prevalence of NASH in
adults in North America is 18.5% in obese and 2.7% in nonobese individuals.1 Of obese individuals
found to have NASH at autopsy, about one in seven had bridging fibrosis or cirrhosis.…
Continue
Posted on May 16, 2008 at 4:00pm —
Comment Wall
You need to be a member of Nashion to add comments!
Join this Ning Network